Company Announcement: Acquisition of Nualtra

Published 21 December 2020

Company Announcement: Acquisition of Nualtra

Nualtra’s purpose is to give patients the best experience possible of medical nutrition whilst delivering the most innovative solutions and better value to the healthcare professional. We call this ‘Better Value, Better Lives’.

Today, we are pleased to announce the exciting news that Ajinomoto Cambrooke has completed its acquisition of Nualtra Limited.

Ajinomoto is a Japanese food and biotechnology corporation and is one of the largest food companies in the world. Their headquarters are based in Tokyo with over 100 subsidiaries worldwide. The group is listed on the Tokyo stock exchange with a market cap of €10bn and revenues in excess of €9bn. Their business foundation is ‘Eat well, live well’ and they lead the world in development of amino acids. In 2007 they completed the strategic acquisition of Cambrooke Therapeutics which signaled a strong intention to develop their healthcare portfolio.

Cambrooke is located in Boston, MA, and is focused primarily on the inherited metabolic disorder and ketogenic diet for intractable epilepsy markets. They hold unique formulations across their portfolio and distribute from their production base in the US. They have commercial operations in the US, Canada, parts of Latin America, across Europe (including the UK) and Australia.

By combining the capabilities of our two organisations, we will strengthen our ability to better serve the needs of our customers and patients.

Nualtra will continue to be an Irish incorporated business with offices in Ireland and the UK. With the broader support of a world-leading food group, Nualtra will further its mission to bring unrivalled products and services to the healthcare services it works with.

We anticipate a smooth transition of ownership, that will bring several observable improvements in the future.

There will no change to our brand names and you will continue to receive the high level of customer service excellence you would expect.

For more information or to ask a question please contact support@nualtra.ie or call Mark Lane +447470 411386

 

About Ajinomoto Cambrooke – Founded in 2000, a proud member of The Ajinomoto Group, is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. Ajinomoto Cambrooke, Inc. works with physicians and researchers from around the world to develop, test, and commercialize products that are focused on inborn errors of metabolism, intractable epilepsy, oncology, cystic fibrosis, and severe protein allergy. More information is available at cambrooke.com

About Nualtra – Nualtra is incorporated in Ireland and has an office located in Limerick. Its principle activity is to develop and provide medical foods to public health systems, for the treatment of patients with disease related malnutrition. These foods are a regulated FMSPs (Food for Special Medical Purpose) and mostly taken orally, although some can be administered via a feeding tube. The ingredients and formulas are owned by Nualtra, manufactured in several European Locations and distributed via pharmaceutical wholesalers. Products are exclusively sold to the NHS & HSE and reimbursed only once they have been prescribed by a doctor. https://nualtra.com

About Ajinomoto Co., Inc.

The Ajinomoto Group, by unlocking the power of amino acids, aims to resolve food and health issues associated with dietary habits and aging, and contribute to greater wellness for people worldwide. Based on the corporate message “Eat Well, Live Well.”, we have been scientifically pursuing the possibilities of amino acids to aim for future growth by creating new value through sustainable and innovative solutions for communities and society. The Ajinomoto Group has offices in 35 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2019, sales were 1.1000 trillion yen (10.1 billion U.S. dollars). To learn more, visit www.ajinomoto.com.